reference/21724239

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21724239

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
issn	2468-2942
pageRange	100433-
publicationName	Cancer Treatment and Research Communications
startingPage	100433
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c836f11f8f11b2a1fd8e87991cb29fc1 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d078ef4750b0bad32ea9d3d6f057ad8b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_74ed45dd0fb6436d1a5d9f58a6317cd9 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_88e7c22574311b3ff09bb02191f9d7c7
bibliographicCitation	Shirasuna K, Koelsch G, Seidel-Dugan C, Salmeron A, Steiner P, Winston WM, Brodkin HR, Nirschl CJ, Abbott S, Kinugasa F, Sugahara S, Ohori M, Takeuchi M, Hicklin DJ, Yoshida T. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody. Cancer Treatment and Research Communications. 2021;28():100433. doi: 10.1016/j.ctarc.2021.100433.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3a189ab7a0b83c1137fc15797124224f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bdad86b95593d17643a14f8d99603820 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23403fe1a2e10809ce39091b17ab884c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_36cb79ab9ce2454de9eb52524609e779 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_135edf6d95e18f862695903d6f327b99 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d4592e7b9dbd0389d6b97792446cdd3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_637e016fe7763bea269fc3a53d09d4b2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a809437d8ca2190a2551fcb30608767 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c56c5d92caed7958b019e99ae68d195e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce86c082866676b6c07e3f19b8c4294d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c852f61eca3788c26ce22b7a42e4810c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df211e035ebc601b2cc939a948a1e56b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e0e72d695099574854467b420733afae http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7c6af8ae5d496c926424dae6a61697c3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0fde1efd7e2983af792e30db4d5aace3
date	2021
identifier	https://pubmed.ncbi.nlm.nih.gov/34273876 https://doi.org/10.1016/j.ctarc.2021.100433
isPartOf	https://portal.issn.org/resource/ISSN/2468-2942 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/45839
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody
discusses	http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0555282 http://id.nlm.nih.gov/mesh/M0018602
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000911Q000627 http://id.nlm.nih.gov/mesh/D007167Q000379 http://id.nlm.nih.gov/mesh/D011971Q000037
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000911Q000494 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D051379
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6057 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_68000b5f90a1d5b5b1a93dbb8aa92d3e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c1da861a271010c66f326fc0e7473dbb http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_beda6fe677b7a43d27c994ffcbd5e2d6 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_29f84c0d894769b14b36c5f43f54153e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7d6a1edc08997e3d7b61d7a07051efb5 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Showing number of triples: 1 to 52 of 52.